Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.50 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22409485 | 1.00 | MTNR1A (0.50) | MTNR1AMTNR1BPLA2G2AHTR2AHRH1 | |
| SCHEMBL26648108 | 0.83 | MTNR1A (0.50) | MTNR1AMTNR1BPLA2G2APLA2G10MAOA | |
| SCHEMBL21191728 | 0.83 | PPARA (0.46) | MTNR1AMTNR1BCYP3A4 | |
| SCHEMBL21523852 | 0.81 | MTNR1A (0.49) | MTNR1AMTNR1BPLA2G2AHTR2AHRH1 | |
| SCHEMBL21523853 | 0.81 | MTNR1A (0.49) | MTNR1AMTNR1BPLA2G2AHTR2AHRH1 | |
| SCHEMBL2953412 | 0.81 | MTNR1A (0.46) | MTNR1AMTNR1BPLA2G2AHTR2AHRH1 | |
| SCHEMBL2953408 | 0.81 | MTNR1A (0.46) | MTNR1AMTNR1BPLA2G2AHTR2AHRH1 | |
| SCHEMBL4901823 | 0.79 | MTNR1A (0.50) | MTNR1AMTNR1BPLA2G2APLA2G10MAOA | |
| SCHEMBL2943414 | 0.79 | MTNR1A (0.47) | MTNR1AMTNR1BPLA2G2APLA2G10MAOA | |
| SCHEMBL1743690 | 0.79 | MTNR1A (0.50) | MTNR1AMTNR1BPLA2G2APLA2G10MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11111259-B2 | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders | UNITY BIOTECHNOLOGY, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| EP-3743069-A1 | BCL-2 PROTEINS DEGRADERS FOR CANCER TREATMENT | BioVentures, LLC (US) | 2020-12-02 | — | — | EP | disclosed |
| US-20200291050-A1 | ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS | UNITY BIOTECHNOLOGY, INC. | 2020-09-17 | — | — | US | disclosed |
| WO-2019144117-A1 | BCL-2 PROTEINS DEGRADERS FOR CANCER TREATMENT | BIOVENTURES, LLC (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11111259-B2 | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders | ACAT1, ARSA, GLA | MTNR1A 1154/4885MTNR1B 1097/4885PLA2G2A 2357/4885 |
| US-20200291050-A1 | ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS | ACAT1, ARSA, GLA | MTNR1A 1154/4885MTNR1B 1097/4885PLA2G2A 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.